Prolactin, hyperprolactinaemia and antipsychotic treatment: A review and lessons for treatment of early psychosis

Journal of Psychopharmacology

Volumn 26, Issue , 2012, Pages 42-51

  Cookson, John ^a   Hodgson, Richard ^b   Wildgust, Hiram J ^c  

^a Mile End Hospital   (United Kingdom)

^b Lyme Brook Centre   (United Kingdom)

^c Hiram Consulting   (United Kingdom)

Author keywords

Antipsychotic; dopamine; first episode; hyperprolactinaemia; osteoporosis; prolactin; psychosis; schizophrenia; sexual dysfunction; side effects; smoking

Indexed keywords

NEUROLEPTIC AGENT; PROLACTIN;

BLOOD; CHEMICALLY INDUCED DISORDER; HUMAN; HYPERPROLACTINEMIA; PSYCHOSIS; REVIEW;

ANTIPSYCHOTIC AGENTS; HUMANS; HYPERPROLACTINEMIA; PROLACTIN; PSYCHOTIC DISORDERS;

EID: 84866238212     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112442016     Document Type: Review

References (97)

1. Abel KM Heatlie HF. (2008) Sex and age specific incidence of fractures in mental illness: an historical population-based cohort study. J Clin Psychiatry 69: 1398–1403.
2. Aichhorn W Marksteiner J Walch T. (2007) Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. J Child Adolesc Psychopharmacol 17: 665–674.
3. Alexiadis M Whitehorn D Woodley H. (2002) Prolactin elevation with quetiapine. Am J Psychiatry 159: 1608–1609.
4. Alfaro CL Wudarsky M Nicolson R. (2002) Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol 12: 83–91.
5. Arakawa R Okumura M Ito H. (2010) Positron emission tomography measurement of dopamine D2 receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry 71: 1131–1137.
6. Aston J Rechsteiner E Bull N. (2010) Hyperprolactinaemia in early psychosis—not only due to antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 34: 1342–1344.
7. Baptista T LaCruz A Meza T. (2001) Antipsychotic drugs and obesity: Is prolactin involved? Can J Psychiatry 46: 829–834.
8. Berwaerts J Cleton A Rossenu S. (2010) A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol 24: 1011–1018.
9. Biller BMK Baum HB Rosenthal DI. (1992) Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 75: 692–697.
10. Biller BM Coughlin JF Saxe V. (1991) Osteopenia in women with hypothalamic amenorrhea: a prospective study. Obstet Gynecol 78: 996–1001.
11. Buhagiar K Cassar JR (2008) Prolactin levels during long-term risperidone treatment in children and adolescents: a cross-sectional study. German Journal of Psychiatry 11: 45–50.
12. Buschlen J Berger GE Borgwardt SJ. (2011) Pituitary volume increase during emerging psychosis. Schizophr Res 125: 41–48.
13. Bushe C Shaw M (2007) Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol 21: 768–773.
14. Bushe C Yeomans D Floyd T. (2008) Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. J Psychopharmacol 22: 56–62.
15. Byerly M Suppes T Tran QV. (2007) Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 27: 639–661.
16. Cookson JC (1981) Oestrogens, dopamine and mood. Br J Psychiatry 139: 365–366.
17. Cookson JC Kennedy NM Gribbon D (1986) Weight gain and prolactin levels in patients on long-term antipsychotic mediation: a double-blind trial of haloperidol decanoate and fluphenazine decanoate. Int Clin Psychopharmacol 1: 41–51.
18. Cookson JC Moult PJA. (1983) The relationship between prolactin levels and clinical ratings in manic patients treated with oral and intravenous test doses of haloperidol. Psychol Med 13: 279–285.
19. Cookson JC Silverstone T Rees L H (1982) Plasma prolactin and growth hormone levels in manic patients treated with pimozide. Br J Psychiatry 140: 274–280.
20. Di Somma C Colao A Di Sarno A. (1998) Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 83: 807–813.
21. Fernandez-Egea E Oliveira C Justicia A. (2012) Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis. Schizophr Res, 134, 16–19.
22. Green AI Faraone SV Brown WA (1990) Prolactin shifts after neuroleptic withdrawal. Psychiatr Res 32: 213–219.
23. Gregg C Shikar V Larsen P. (2007) White matter plasticity and enhanced remyelination in the maternal CNS. J Neurosci 27: 1812–1823.
24. Gruen PH Sachar E J Langer G. (1978) Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry 35:106–116.
25. Haas M Eerdekens M Kushner S. (2009) Efficacy, safety and tolerability of two risperidone dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry 194: 158–164.
26. Haddad PM Wieck A (2004) Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management. Drugs 64: 2291–2314.
27. Halbreich U Kahn LS (2003) Hyperprolactinemia and schizophrenia: Mechanisms and clinical aspects. J Psychiatr Pract 9: 344–353.
28. Haney EM Warden SJ (2008) Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies. J Musculoskelet Neuronal Interact 8: 133–145.
29. Harvey PW Everett DJ Springall CJ (2008) Adverse effects of prolactin in rodents and humans: breast and prostate cancer. J Psychopharmacol 22: 20–27.
30. Hay ID Wass JAH (2008) Clinical endocrine oncology. John Wiley & Sons. 238.
31. Hippisley-Cox J Vinogradova Y Coupland C. (2007) Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study. Arch Gen Psychiatry 64: 1368–1376.
32. Howard L Kirkwood G Leese M (2007) Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 190: 129–134.
33. Howes OD Wheeler MJ Pilowsky LS. (2007) Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J Clin Psychiatry 3: 361–367.
34. Kahn RS Fleischhacker WW Boter H. (2008) Effectiveness of antipsychotic drugs in first episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371: 1085–1097.
35. Kapur S Langlois X Vinken P. (2002) The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis of results in rats. J Pharmacol Exp Ther 302: 1129–-1134.
36. Kapur S Zipursky R Jones C. (2000) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57: 553–559.
37. Kelly DL Conley RR (2006) A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology 31: 340–346.
38. Kishimoto T Watanabe K Shimado N. (2008) Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry 69: 385–391.
39. Klibanski A Neer RM Beitins IZ. (1980) Decreased bone density in hyperprolactinemic women. N Engl J Med 303: 1511–1514.
40. Knegtering Castelein S Bous H. (2004) A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 24: 56–61.
41. Kuruvilla A Peedicayil J Srikrishna G. (1992) A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 19: 603–606.
42. Langer G Sachar EJ Halpern FS. (1977a) The prolactin response to neuroleptic drugs. A test of dopaminergic blockade: neuroendocrine studies in normal man. J Clin Endocrinol Metab 45: 996–1002.
43. Langer G Sachar EJ Gruen PH. (1977b) Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency: dopamine hypothesis supported in man. Nature 266: 639–640.
44. Leucht S Burkard T Henderson JH. (2007) Physical illness and schizophrenia. Cambridge: Cambridge Press.
45. Lieberman JA Stroup TS McEvoy JP. (2005) Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223.
46. Lin CH Huang KH Chang YC. (2011) Clozapine protects bone mineral density in female patients with schizophrenia. Int J Neuropsychopharmacol. Epub ahead of print 10 October 2011.
47. Lopez-Rodrıguez R Roman M Novalbos J. (2011) DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers. J Clin Psychopharmacol 31: 555–562.
48. Mackin P Waton A Nulkar A. (2011). Prolactin and smoking status in antipsychotic-treated patients. J Psychopharmacol 25: 698–703.
49. Malik P Kemmler G Hummer M. (2011). Sexual dysfunction in first-episode schizophrenia patients: results from european first episode schizophrenia trial. J Clin Psychopharmacol: 31, 274–280.
50. Mancini T Casanueva FF Giustina A (2008) Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 37: 67–99.
51. McEvoy JP Lieberman JA Perkins DO. (2007) Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52- week comparison. Am J Psychiatry 164: 1050–1060.
52. McEvoy JP Lieberman JA Stroup TS. (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163: 600–610.
53. McIlhinney S Smith M (2008) Depot risperidone, hyperprolactinaemia and prolactin-associated side effects. Psychiatr Bull 32: 358–359.
54. Melmed S Jameson JL (2005) Disorders of the anterior pituitary and hypothalamus. In: Jameson JN Kasper DL Harrison TR et al. (eds) Harrison’s principles of internal medicine. New York: McGraw-Hill Medical Publishing Division.
55. Meltzer HY Goode D Schyve PM. (1979) Effect of clozapine on human serum prolactin levels. Am J Psychiatry 136: 1550–1555.
56. Mir A Shivakumar K Williamson RJ. (2008) Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol 22: 244–253.
57. Montgomery J Winterbottom E Jessani M. (2004) Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry 65: 1491–1498
58. Nakonezny PA Byerly MJ Rush A J (2007) The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. J Sex Marital Ther 33: 203–216.
59. National Institute for Health and Clinical Excellence (NICE) (2007) The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Clinical Practice Guideline Number 38 commissioned by the National Collaborating Centre for Mental Health published by The British Psychological Society and Gaskell. (www.nice.org.uk).
60. National Institute for Health and Clinical Excellence (NICE) (2009) NICE clinical guideline 82. Schizophrenia: Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. Update of NICE clinical guideline 1. (www.nice.org.uk).
61. O’Keane V (2008) Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 22: 70–75.
62. Pappagallo M Silva R (2004). The effect of atypical antipsychotic agents on prolactin levels in children and adolescents. J Child Adolesc Psychopharmacol 14: 359–371.
63. Perez-Iglesias R Crespo-Facorro B Amodo JA. (2007) A 12 week randomized clinical trial to evaluate metabolic changes in drug naïve, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry 68: 1733–1740.
64. Peveler RC Branford D Citrome L. (2008) Antipsychotic associated hyperprolactinaemia: Clinical ecommendations. J Psychopharmacol 22: 98-103.
65. Poyraz BC Aksoy C Balcioğlu I (2008) Increased incidence of autoimmune thyroiditis in patients with antipsychotic-induced hyperprolactinemia. Eur Neuropsychopharmacol 18: 667–672.
66. Rao VA Bishop M Coppen A (1980) Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia. Br J Psychiatry 137: 518–521.
67. Rich TD (1984) Sulpiride: assessment of a pharmacologically and chemically distinct neuroleptic. Med Hypotheses 14: 69–81.
68. Robinson DG Woerner MG Napolitano B. (2006) Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry 163: 2096–2102.
69. Roke Y van Harten PN. (2009) Antipsychotic medication in children and adolescents: A descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol 19: 403–414.
70. Rosen CJ (2009) Serotonin rising – The bone, brain, bowel connection. N Engl J Med 360: 957–959.
71. Rybakowski JK Dmitrzak-Weglarz M. (2012) Functional –1149 G/T polymorphism of the prolactin gene in schizophrenia. Neuropsychobiology 65: 41–44.
72. Saito E Correll CU Gallelli K. (2004) A prospective study of hyperprolactinaemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol 14: 350–358.
73. Schooler N Rabinowitz J Davidson M. (2005) Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial. Am J Psychiatry 162: 947–953.
74. Serri O Chik CL Ur E. (2003) Diagnosis and management of hyperprolactinemia. CMAJ 169: 575–581.
75. Shim J-C Shin J-G K Kelly DL. (2007) Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: A placebo-controlled trial. Am J Psychiatry 164: 1404–1410.
76. Sikich L Frazier JA McClellan J. (2008) Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study. Am J Psychiatry 165: 1420–1431.
77. Silverstone Cookson (1983) Examining the dopamine hypotheses of schizophrenia and of mania using the prolactin response to antipsychotic drugs. Neuropharmacology 22: 539–541.
78. Slattery DA Neumann ID (2008) Prolactin is involved in maternal behaviour and stress related alterations in the HPA axis. J Physiol 586: 377-385.
79. Smith S (2008) The impact of hyperprolactinaemia on sexual function in patients with psychosis. J Psychopharmacol 22: 63-69.
80. Stevenaert A Beckers A Vandalem JL. (1986) Early normalization of luteinizing hormone pulsatility after successful transsphenoidal surgery in women with microprolactinomas. J Clin Endocrinol Metab 62: 1044–1047.
81. Stevens JR Kymissis PI Baker AJL (2005) Elevated prolactin levels in male youths treated with risperidone and quetiapine. J Child Adolesc Psychopharmacol 15: 893–900.
82. Stroup TS Lieberman JA McEvoy JP. (2006) Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163: 611–622.
83. Stroup TS Lieberman JA McEvoy JP. (2007) Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE study. Am J Psychiatry 164: 415–427.
84. Sugawara N Yasui-Furukori N Fujii A. (2011) No association between bone mass and prolactin levels among patients with schizophrenia. Human Psychopharmacology: Clinical and Experimental 26: 596–601.
85. Svestka J Synek O Tomanová J. (2007) Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. Neuro Endocrinol Lett 28: 881–888.
86. Szarfman A Tonning J Levine JG. (2006) Atypical antipsychotics and pituitary tumours: a pharmacovigilance study. Pharmacotherapy 26: 748–758.
87. Tohen M Kryzhanovskaya L Carlson G. (2007) Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 164: 547–1556.
88. Turrone P Kapur S Seeman MV. (2002) Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 159: 133–135.
89. Tworoger S Eliassen H Sluss P. (2007) A prospective study of plasma prolactin concentrations and the risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 25: 1–7.
90. Tworoger SS Sluss P Hankinson SE (2006) Association between plasma prolactin concentrations and risk of breast cancer among predominantly premenopausal women. Cancer Res 66: 2476–2482
91. Wang PS Walker AM Tsuang MT. (2002) Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 59: 1147–1154.
92. Wiles D Franklin M Dencker S J. (1980) Plasma fluphenazine and prolactin levels in schizophrenic patients during treatment with low and high doses of fluphenazine enanthate. Psychopharmacology (Berl) 71: 131–136.
93. Wudarsky M Nicolson R Hamburger SD. (1999) Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 9: 239–245.
94. Yasui-Furukori N Fujii A Sugawara N. (2012) No association between hormonal abnormality and sexual dysfunction in Japanese schizophrenia patients treated with antipsychotics. Human Psychopharmacology: Clinical and Experimental, 27: 82–89.
95. Young R Lawford BR Barnes M. (2004) Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry 185: 147–151.
96. Zhang XR Zhang ZJ Zhu RX. (2011) Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. Pharmacogenetics 12: 1127–1136.
97. Zipursky RB Gu H Green AI. (2005) Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 187: 537–543.